In a nutshell The aim of this study was to evaluate the safety of giving stereotactic radiosurgery (SRS) at the same time as other cancer treatments for patients who have brain metastasis. The study found that SRS given in combination with chemotherapy, immunotherapy, or targeted therapy was safe with low levels of side effects. Some background The...
Read More
In a nutshell The aim of this study was to evaluate the safety of giving stereotactic radiosurgery (SRS) at the same time as other cancer treatments for patients who have brain metastasis. The study found that SRS given in combination with chemotherapy, immunotherapy, or targeted therapy was safe with low levels of side effects. Some background The...
Read More
In a nutshell The aim of this study was to evaluate the safety of giving stereotactic radiosurgery (SRS) at the same time as other cancer treatments for patients who have brain metastasis. The study found that SRS given in combination with chemotherapy, immunotherapy, or targeted therapy was safe with low levels of side effects. Some background The...
Read More
In a nutshell The aim of this study was to evaluate the safety of giving stereotactic radiosurgery (SRS) at the same time as other cancer treatments for patients who have brain metastasis. The study found that SRS given in combination with chemotherapy, immunotherapy, or targeted therapy was safe with low levels of side effects. Some background...
Read More
In a nutshell This study compared the use of chemotherapy and bevacizumab (Avastin) or panitumumab (Vectibix) for the treatment of left-sided metastatic colorectal cancer (mCRC) without BRAF/RAS mutations (permanent changes in genes). The study found that both treatment options are effective for these patients. Some background Patients who...
Read More
In a nutshell This study compared the use of pembrolizumab (Keytruda) to chemotherapy for the treatment of patients with colorectal cancer (CRC) and high microsatellite instability (MI). This study showed that patients who received pembrolizumab had a better outcome than those who were given chemotherapy. Some background Patients who are...
Read More
In a nutshell This study compared the effectiveness of regorafenib (Stivarga), trifluridine/tipiracil (TFTP; Lonsurf), and combinations of these drugs in the treatment of patients with inoperable colorectal cancer. Researchers suggested that a combination of TFTP and regorafenib is associated with longer survival and fewer side effects. Some...
Read More
In a nutshell The study evaluated the optimal timing of surgery for colorectal cancer liver metastasis (CRLM) after chemotherapy (CT). The main finding was that surgery within 5 weeks after CT may improve patients' outcomes. Some background Chemotherapy (CT) is used before surgery to remove tumors to reduce tumor size. This is...
Read More
In a nutshell This study investigated the effectiveness of irinotecan (Camptosar) with and without cetuximab (Erbitux) in the treatment of metastatic (spread to other parts of the body) colorectal cancer (mCRC). Researchers suggested that combined treatment improves the outcomes of these patients. Some background Colorectal cancer (CRC) is one of...
Read More
In a nutshell The study compared outcomes of lorlatinib (Lorbrena) with crizotinib (Xalkori) in patients with previously untreated advanced non-small-cell lung cancer (NSCLC) with ALK mutations (genetic abnormalities). The main finding was that patients receiving lorlatinib had longer progression-free survival (PFS) and a higher response in the...
Read More
In a nutshell This trial is looking to examine the safety and effectiveness of a new drug called CYH33 in combination with olaparib (Lynparza) for the treatment of advanced solid tumors including prostate cancer. The main outcomes that are to be measured are side effects and the response rate to the treatment. This trial is being carried out in Houston,...
Read More
In a nutshell This study looked at the effectiveness of immune therapy in patients aged over 65 with advanced melanoma. They found that immune therapy led to longer survival times than other treatments such as chemotherapy. Some background Immune therapy has improved the outlook for patients with advanced skin melanoma. These medications...
Read More
